Polynovo (PNV.AX) Stock Price

Polynovo Price

ASX·CLOSED
0.87AUD+0.02 (+2.34 %)
Market closed

Revenue has compounded at 27.4% per year over the past 19 years to 127.73 M AUD. Polynovo's net margin stands at 10.3%, up from -15.8% several years earlier. Analysts set a median price target of 2.04 AUD, implying 135.8% above the current price. Of 11 analysts, 9 rate the stock a buy — an overall Buy consensus. The stock trades about 3% above its 52-week low.

Polynovo stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Polynovo over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Polynovo stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Polynovo's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Polynovo Stock Price History
DatePolynovo Price
7/31/20260.87 AUD
7/30/20260.85 AUD
7/29/20260.88 AUD
7/28/20260.85 AUD
7/27/20260.84 AUD
7/24/20260.86 AUD
7/23/20260.93 AUD
7/22/20260.95 AUD
7/21/20260.95 AUD
7/20/20260.97 AUD
7/17/20260.98 AUD
7/16/20261.03 AUD
7/15/20261.00 AUD
7/14/20261.01 AUD
7/13/20261.01 AUD
7/10/20261.03 AUD
7/9/20261.03 AUD
7/8/20261.00 AUD
7/7/20261.00 AUD
7/6/20261.00 AUD
7/3/20260.97 AUD
7/2/20260.93 AUD
7/1/20260.93 AUD
6/30/20260.91 AUD
6/29/20260.94 AUD
6/26/20260.92 AUD
6/25/20260.94 AUD
6/24/20260.94 AUD
6/23/20260.95 AUD
6/22/20260.96 AUD
6/19/20261.02 AUD
6/18/20261.02 AUD
6/17/20261.00 AUD
6/16/20261.00 AUD
6/15/20260.98 AUD
6/12/20260.98 AUD
6/11/20261.01 AUD
6/10/20261.04 AUD
6/9/20261.04 AUD
6/5/20261.05 AUD
6/4/20261.07 AUD
6/3/20261.08 AUD
6/2/20261.11 AUD
6/1/20261.16 AUD
5/29/20261.22 AUD
5/28/20261.25 AUD
5/27/20261.21 AUD
5/26/20261.24 AUD
5/25/20261.27 AUD
5/22/20261.13 AUD
5/21/20261.13 AUD
5/20/20261.04 AUD
5/19/20261.06 AUD
5/18/20261.06 AUD
5/15/20261.20 AUD
5/14/20261.16 AUD
5/13/20261.01 AUD
5/12/20260.94 AUD
5/11/20261.02 AUD
5/8/20261.01 AUD
5/7/20261.04 AUD
5/6/20261.02 AUD
5/5/20261.00 AUD
5/4/20261.00 AUD
5/1/20261.00 AUD
4/30/20261.00 AUD
4/29/20261.01 AUD
4/28/20260.99 AUD
4/27/20261.00 AUD
4/24/20261.00 AUD
4/23/20261.02 AUD
4/22/20261.01 AUD
4/21/20261.02 AUD
4/20/20261.01 AUD
4/17/20261.01 AUD
4/16/20261.00 AUD
4/15/20261.02 AUD
4/14/20261.03 AUD
4/13/20261.05 AUD
4/10/20260.96 AUD
4/9/20260.94 AUD
4/8/20260.98 AUD
4/7/20260.93 AUD
4/2/20260.94 AUD
4/1/20261.00 AUD
3/31/20260.94 AUD
3/30/20260.89 AUD
3/27/20260.89 AUD
3/26/20260.89 AUD
3/25/20260.89 AUD
3/24/20260.88 AUD
3/23/20260.89 AUD
3/20/20260.91 AUD
3/19/20260.91 AUD
3/18/20260.94 AUD
3/17/20260.94 AUD
3/16/20260.95 AUD
3/13/20260.94 AUD
3/12/20260.94 AUD
3/11/20260.95 AUD
3/10/20260.90 AUD
3/9/20260.88 AUD
3/6/20260.94 AUD
3/5/20260.93 AUD
3/4/20260.88 AUD
3/3/20260.90 AUD
3/2/20260.94 AUD
2/27/20260.96 AUD
2/26/20260.98 AUD
2/25/20260.94 AUD
2/24/20260.93 AUD
2/23/20260.90 AUD
2/20/20260.92 AUD
2/19/20261.00 AUD
2/18/20260.98 AUD
2/17/20260.95 AUD
2/16/20260.93 AUD
2/13/20260.92 AUD
2/12/20260.93 AUD
2/11/20261.00 AUD
2/10/20261.00 AUD
2/9/20260.94 AUD
2/6/20260.92 AUD
2/5/20261.00 AUD
2/4/20260.97 AUD
2/3/20260.99 AUD
2/2/20260.99 AUD
1/30/20261.01 AUD
1/29/20261.03 AUD
1/28/20261.03 AUD
1/27/20261.09 AUD
1/23/20261.09 AUD
1/22/20261.12 AUD
1/21/20261.12 AUD
1/20/20261.13 AUD
1/19/20261.20 AUD
1/16/20261.21 AUD
1/15/20261.20 AUD
1/14/20261.22 AUD
1/13/20261.20 AUD
1/12/20261.20 AUD
1/9/20261.23 AUD
1/8/20261.25 AUD
1/7/20261.21 AUD
1/6/20261.17 AUD
1/5/20261.23 AUD
1/2/20261.25 AUD
12/31/20251.23 AUD
12/30/20251.24 AUD
12/29/20251.27 AUD
12/24/20251.28 AUD
12/23/20251.26 AUD
12/22/20251.25 AUD
12/19/20251.23 AUD
12/18/20251.18 AUD
12/17/20251.16 AUD
12/16/20251.17 AUD
12/15/20251.22 AUD
12/12/20251.21 AUD
12/11/20251.24 AUD
12/10/20251.22 AUD
12/9/20251.20 AUD
12/8/20251.19 AUD
12/5/20251.21 AUD
12/4/20251.20 AUD
12/3/20251.20 AUD
12/2/20251.18 AUD
12/1/20251.18 AUD
11/28/20251.23 AUD
11/27/20251.20 AUD
11/26/20251.21 AUD
11/25/20251.20 AUD
11/24/20251.16 AUD
11/21/20251.13 AUD
11/20/20251.14 AUD
11/19/20251.11 AUD
11/18/20251.13 AUD
11/17/20251.17 AUD
11/14/20251.16 AUD
11/13/20251.20 AUD
11/12/20251.24 AUD
11/11/20251.23 AUD
11/10/20251.23 AUD
11/7/20251.20 AUD
11/6/20251.22 AUD
11/5/20251.27 AUD
11/4/20251.29 AUD
11/3/20251.26 AUD
10/31/20251.32 AUD
10/30/20251.38 AUD
10/29/20251.36 AUD
10/28/20251.40 AUD
10/27/20251.35 AUD
10/24/20251.29 AUD
10/23/20251.26 AUD
10/22/20251.30 AUD
10/21/20251.34 AUD
10/20/20251.25 AUD
10/17/20251.26 AUD
10/16/20251.40 AUD
10/15/20251.38 AUD
10/14/20251.39 AUD
10/13/20251.37 AUD
10/10/20251.49 AUD
10/9/20251.47 AUD
10/8/20251.47 AUD
10/7/20251.46 AUD
10/6/20251.54 AUD
10/3/20251.50 AUD
10/2/20251.47 AUD
10/1/20251.40 AUD
9/30/20251.42 AUD
9/29/20251.38 AUD
9/26/20251.38 AUD
9/25/20251.46 AUD
9/24/20251.45 AUD
9/23/20251.49 AUD
9/22/20251.48 AUD
9/19/20251.57 AUD
9/18/20251.63 AUD
9/17/20251.58 AUD
9/16/20251.60 AUD
9/15/20251.52 AUD
9/12/20251.44 AUD
9/11/20251.46 AUD
9/10/20251.40 AUD
9/9/20251.38 AUD
9/8/20251.47 AUD
9/5/20251.52 AUD
9/4/20251.41 AUD
9/3/20251.38 AUD
9/2/20251.45 AUD
9/1/20251.32 AUD
8/29/20251.32 AUD
8/28/20251.36 AUD
8/27/20251.35 AUD
8/26/20251.26 AUD
8/25/20251.20 AUD
8/22/20251.10 AUD
8/21/20251.13 AUD
8/20/20251.11 AUD
8/19/20251.13 AUD
8/18/20251.21 AUD
8/15/20251.18 AUD
8/14/20251.18 AUD
8/13/20251.15 AUD
8/12/20251.16 AUD
8/11/20251.17 AUD
8/8/20251.14 AUD
8/7/20251.17 AUD
8/6/20251.19 AUD
8/5/20251.19 AUD
8/4/20251.21 AUD
Access this data via the Eulerpool API
Get Free API Key

Polynovo Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
66.11 M AUD
-5.32 M AUD
-4.92 M AUD
Jan 1, 2024
104.73 M AUD
2.70 M AUD
5.26 M AUD
Jan 1, 2025
127.73 M AUD
4.97 M AUD
13.21 M AUD
Jan 1, 2026 (e)
155.10 M AUD
-5.11 M AUD
5.77 M AUD
Jan 1, 2027 (e)
180.65 M AUD
-5.95 M AUD
17.77 M AUD
Jan 1, 2028 (e)
216.51 M AUD
-7.13 M AUD
27.32 M AUD
Jan 1, 2029 (e)
226.10 M AUD
-7.45 M AUD
34.63 M AUD
Jan 1, 2030 (e)
235.13 M AUD
65.43 M AUD
46.52 M AUD

Polynovo Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 2, 2026, 2:55 AM
 
REVENUEM AUD
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEM AUD
EBITM AUD
EBIT MARGIN%
NET INCOMEM AUD
NET INCOME GROWTH%
SHARESM
20162017201820192020202120222023202420252026e2027e2028e2029e2030e2031e
3.003.005.0013.0022.0029.0041.0066.00104.00127.00155.00180.00216.00226.00235.00250.00
––66.67160.0069.2331.8241.3860.9857.5822.1222.0516.1320.004.633.986.38
4,066.67133.33100.0092.3190.9193.1095.1292.4295.1996.0696.0696.0696.0696.0696.0696.06
122.004.005.0012.0020.0027.0039.0061.0099.00122.00148.90172.91207.50217.10225.75240.16
-3.00-5.00-6.00-3.00-4.00-3.00–-5.002.004.00-5.00-5.00-7.00-7.0065.00–
-100.00-166.67-120.00-23.08-18.18-10.34–-7.581.923.15-3.23-2.78-3.24-3.1027.66–
-3.00-5.00-5.00-3.00-4.00-4.00-1.00-4.005.0013.005.0017.0027.0034.0046.0057.00
200.0066.67–-40.0033.33–-75.00300.00-225.00160.00-61.54240.0058.8225.9335.2923.91
493.26561.76627.89659.66661.09661.19660.87684.45700.38692.62692.62692.62692.62692.62692.62692.62
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Polynovo generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Polynovo retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Polynovo's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Polynovo has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Polynovo's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Polynovo stock margins

The Polynovo margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Polynovo. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Polynovo.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2021
94.67 %
-10.79 %
-15.79 %
Jan 1, 2022
94.68 %
-0.62 %
-2.88 %
Jan 1, 2023
93.29 %
-8.04 %
-7.45 %
Jan 1, 2024
94.77 %
2.58 %
5.02 %
Jan 1, 2025
95.93 %
3.89 %
10.35 %
Jan 1, 2026 (e)
95.93 %
-3.29 %
3.72 %
Jan 1, 2027 (e)
95.93 %
-3.29 %
9.83 %
Jan 1, 2028 (e)
95.93 %
-3.29 %
12.62 %

Polynovo Stock Revenue, EBIT, Earnings per Share

The Polynovo earnings per share therefore indicates how much revenue Polynovo has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2021
0.04 AUD
-0.00 AUD
-0.01 AUD
Jan 1, 2022
0.06 AUD
-0.00 AUD
-0.00 AUD
Jan 1, 2023
0.10 AUD
-0.01 AUD
-0.01 AUD
Jan 1, 2024
0.15 AUD
0.00 AUD
0.01 AUD
Jan 1, 2025
0.18 AUD
0.01 AUD
0.02 AUD
Jan 1, 2026 (e)
0.22 AUD
-0.01 AUD
0.01 AUD
Jan 1, 2027 (e)
0.26 AUD
-0.01 AUD
0.03 AUD
Jan 1, 2028 (e)
0.31 AUD
-0.01 AUD
0.04 AUD

Polynovo business model & stock analysis

Polynovo Ltd is an Australian BioTech company that specializes in the development and manufacturing of medical implants. The company was founded in 1986 under the name Regeneus Ltd and is headquartered in Melbourne. Polynovo's history began with the development of products for the veterinary field. In 2000, the company received approval for the sale of its first human products, which were used for wound treatment. In 2014, the company was renamed Polynovo to emphasize its focus on biological implants for human tissue. Polynovo utilizes a revolutionary technology called NovoSorb, which allows for the production of biodegradable polymer films in various shapes and sizes. These are then used as implants in the human body and naturally degrade within a predetermined timeframe. Polynovo is divided into various divisions, including wound care, plastic surgery, and orthopedics. In wound care, the company offers products that aim to prevent infections and promote natural healing processes. The plastic surgery division provides implants for breast reconstruction and fat transplantation. In orthopedics, Polynovo manufactures implants for joints, bones, and tendons. An example of a Polynovo product is NovoSorb BTM (Biodegradable Temporary Matrix), which is used in burns and other skin defects. The matrix stimulates healing and the formation of new tissue, restoring a normal appearance to the patient. Polynovo's business model is based on long-term relationships with hospitals, medical professionals, and government agencies. The company heavily invests in research and development to continuously improve and expand its technology and product range. Through partnerships with other companies and academic institutions, Polynovo is working towards global distribution of its products. Overall, Polynovo has received various awards over the years, including an innovation award from the Australian Trade Commission, and has been recognized multiple times as one of Australia's fastest-growing companies. In conclusion, Polynovo is an innovative and successful company specializing in the development and manufacturing of biological implants. Thanks to its NovoSorb technology, the company can offer products that help accelerate the healing process and facilitate faster patient recovery.

Polynovo SWOT Analysis

Strengths

  • Polynovo Ltd has a strong research and development team, enabling them to continuously innovate and develop new products.
  • The company's patented NovoSorb biodegradable polymer technology provides a distinct competitive advantage in the market.
  • Strong financial performance and steady revenue growth have allowed the company to invest in expansion and infrastructure.
  • Polynovo has a diverse and global customer base, reducing dependence on any single market or customer.

Weaknesses

  • Limited market presence and brand recognition compared to more established competitors.
  • Reliance on a few key suppliers for raw materials, which may expose the company to supply chain risks.
  • High production costs due to the complexity of the manufacturing process and the use of advanced technology.
  • Limited product portfolio, with a focus primarily on medical devices for burn treatment.

Opportunities

  • Growing demand for biodegradable polymers in various industries presents an opportunity for Polynovo to expand its product portfolio.
  • Increasing global healthcare expenditure and the need for advanced wound care products creates a favorable market environment for the company.
  • The potential to enter new geographic markets and form strategic partnerships to accelerate growth.
  • Expansion into other medical device verticals beyond burn treatment, such as wound healing or surgical applications.

Threats

  • Intense competition from larger and more established medical device companies with greater resources and market presence.
  • Regulatory challenges and compliance requirements in different markets may pose obstacles to market entry and product approvals.
  • Economic downturns and fluctuations in healthcare spending could negatively impact Polynovo's sales and growth.
  • Technological advancements or breakthroughs by competitors could render Polynovo's existing products less competitive or obsolete.

Polynovo Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Polynovo historical P/E ratio, EBIT multiple, and P/S ratio

Polynovo annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Polynovo shares outstanding

The number of shares of Polynovo was 692.62 M in 2025. This indicates how many shares Polynovo is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2021
661.19 M Stocks
Jan 1, 2022
660.87 M Stocks
Jan 1, 2023
684.45 M Stocks
Jan 1, 2024
700.38 M Stocks
Jan 1, 2025
692.62 M Stocks
Jan 1, 2026 (e)
692.62 M Stocks
Jan 1, 2027 (e)
692.62 M Stocks
Jan 1, 2028 (e)
692.62 M Stocks

Current Polynovo forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
0.00 %
Buy
81.82 % (9)
Hold
18.18 % (2)
Sell
0.00 % (0)
12M Price Target
2.04
Last Price
0.87
Currency
AUD
12M Return Potential
135.84 %
LTM Return
0 %

Polynovo Earnings Calls

Polynovo Earnings Estimates

DateEPS estimateRevenue EstimateQuarterly report
2/21/20240.00AUD40.30 MAUD2024 Q2
8/24/20230.01AUD34.31 MAUD2023 Q4
2/23/20230.00AUD28.22 MAUD2023 Q2
8/24/20220.00AUD21.52 MAUD2022 Q4
8/26/2021-0.00AUD18.27 MAUD2021 Q4

EESG©

Eulerpool ESG Scorecard© for the Polynovo stock

45/100
15
Environment
75
Social
46
Governance
E

Environment

20
Scope 1 - Direct Emissions—
Scope 2 - Indirect emissions from purchased energy—
Scope 3 - Indirect emissions within the value chain—
Total CO₂ emissions—
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather—
Pesticides—
Palm Oil—
Tobacco
Genetically modified organisms
Climate concept—
Sustainable forestry—
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees42
Percentage of women in management—
Percentage of Asian employees5
Share of Asian management—
Percentage of Hispanic/Latino employees10
Hispano/Latino Management share—
Percentage of Black employees3
Black Management Share—
Percentage of white employees80
White Management Share—
Adult content
Alcohol
Weapons—
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept—
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Polynovo shareholder structure

% Name
3.58885%
State Street Global Advisors Australia Ltd.
State Street Global Advisors Australia Ltd.
2.37820%
FIL Investment Management (Australia) Limited
FIL Investment Management (Australia) Limited
1.93432%
Vanguard Investments Australia Ltd.
Vanguard Investments Australia Ltd.
1.29132%
Allianz Global Investors Asia Pacific Limited
Allianz Global Investors Asia Pacific Limited
1.26650%
BlackRock Institutional Trust Company, N.A.
BlackRock Institutional Trust Company, N.A.
1.25673%
FIL Investment Management (Hong Kong) Limited
FIL Investment Management (Hong Kong) Limited

Polynovo Beneficial Ownership Filings (SEC 13D/G)

Free Float
89.3%
Float Shares
-
Shares Outstanding
-

Polynovo Executives and Management Board

SR

Mr. Swami Raote

Chief Executive Officer

Compensation1.52 M AUD
DM

Dr. David McQuillan

Chief Technical and Scientific Officer · since 2012

Compensation424,157.00 AUD
JG

Mr. Jan Gielen

Chief Financial Officer

Compensation308,070.00 AUD
PS

Mr. Philip Scorgie

Chief Information Officer

Compensation253,614.00 AUD
DW

Mr. David Williams

Non-Executive Independent Chairman of the Board

Compensation139,429.00 AUD

Polynovo Supply Chain

Polynovo Supply Chain

Correlation: how closely stock prices move together

Same directionNo relationOpposite
2 companies
#Name1M3M6M1Y2YTrend
1
Premier A
0.37
0.24
0.80
-0.13
-0.45
2
Establishment Labs Holdings
Supplier
-0.62
-0.26
-0.23
0.66
-0.27

Frequently asked questions about Polynovo

The business model of Polynovo Ltd, an Australian medical device company, is centered around the development, manufacturing, and commercialization of its innovative biodegradable polymer technologies for the medical industry. Polynovo's core product is NovoSorb, a revolutionary biomaterial that can be used in various medical applications, such as wound management, surgical procedures, and tissue regeneration. By harnessing the benefits of NovoSorb, Polynovo aims to provide healthcare professionals with advanced solutions that improve patient outcomes and reduce healthcare costs. With its focus on research, technology, and collaboration, Polynovo Ltd strives to establish itself as a leading player in the global medical device market.

All fundamentals and in-depth analysis of Polynovo

Our stock analysis for Polynovo stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Polynovo. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Polynovo Stock
Polynovo Revenue→
Polynovo Stock
Polynovo Net Income→
Polynovo Stock
Polynovo P/E→
Polynovo Stock
Polynovo P/S→
Polynovo Stock
Polynovo EBIT→
Polynovo Stock
Polynovo Dividend→
Polynovo Stock
Polynovo Directors Dealings→
Polynovo Stock
Polynovo Stocks→
Polynovo Stock
Polynovo Market capitalization→
Polynovo Stock
Polynovo Debt→
Polynovo Stock
Polynovo Liabilities→
Polynovo Stock
Polynovo Equity→
Polynovo Stock
Polynovo AAQS→
Polynovo Stock
Polynovo Employees→
Polynovo Stock
Polynovo ROE→
Polynovo Stock
Polynovo ROA→
Polynovo Stock
Polynovo ROCE→
Polynovo Stock
Polynovo News→
Polynovo Stock
Polynovo Analyst Price Targets→

Health Stocks

PolyPeptide GroupPolylite Taiwan CoPolyrizonPoly MedicurePOMDOCTOR LIMITED American Depositary SharesPolaryx Therapeutics, Inc. Common StockPoniard PharmaceuticalsPolaris Group LLCPorton Pharma SolutionsPolaris AI PharmaPositronPMV PharmaceuticalsAll Stocks A–Z →